aluminum sulfate has been researched along with Diabetes Mellitus, Type 1 in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.57) | 29.6817 |
| 2010's | 16 (57.14) | 24.3611 |
| 2020's | 11 (39.29) | 2.80 |
| Authors | Studies |
|---|---|
| Achenbach, P; Barcenilla, H; Casas, R; Dietrich, F; Ludvigsson, J; Tavira, B; Wahlberg, J | 1 |
| Achenbach, P; Barcenilla, H; Casas, R; Dietrich, F; Ludvigsson, J; Puente-Marin, S; Tavira, B; Wahlberg, J | 1 |
| Hannelius, U; Ludvigsson, J; Nowak, C | 1 |
| Casas, R; Clemente-León, M; Dietrich, F; Ferrer Lozano, M; Gómez-Gila, A; Hanas, R; Hannelius, U; Hernandez, C; Lind, M; Ludvigsson, J; Lundberg, E; Martínez-Brocca, MA; Nattero-Chavez, L; Nowak, C; Pelikanova, T; Pruhova, S; Puente-Marin, S; Rica, I; Ruiz de Adana, M; Sas, T; Sumnik, Z; Wahlberg, J | 1 |
| Fiorina, P; Lunati, ME | 1 |
| Björklund, A; Grill, V; Hals, IK; Ludvigsson, J | 1 |
| Bruggeman, Y; Ellis, D; Gysemans, C; Laureys, J; Martens, PJ; Mathieu, C; Teyton, L; Viaene, M | 1 |
| Choat, HM; Lunsford, AA; Martin, A; McCormick, KL; McGwin, GG; Mick, GJ; Tse, HM | 1 |
| Achenbach, P; Barcenilla, H; Casas, R; Dietrich, F; Ludvigsson, J; Puente-Marin, S | 1 |
| Balasuriya, C; Björklund, A; Casas, R; Grill, V; Hals, IK; Ludvigsson, J | 1 |
| Albin, AK; Arvidsson, CG; Carlsson, A; Casas, R; Hanås, R; Ludvigsson, J; Rathsman, B; Routray, I; Samuelsson, U; Särnblad, S; Vigård, T | 1 |
| Åkerman, L; Axelsson, S; Casas, R; Cheramy, M; Ludvigsson, J; Tavira, B | 1 |
| Ludvigsson, J | 2 |
| Peakman, M; Yeo, L | 1 |
| Achenbach, P; Barcenilla, H; Casas, R; Ludvigsson, J; Tavira, B; Wahlberg, J | 1 |
| Akerman, L; Axelsson, S; Casas, R; Chéramy, M; Hjorth, M; Ludvigsson, J; Mallone, R; Pihl, M | 1 |
| Akerman, L; Axelsson, S; Casas, R; Chéramy, M; Ludvigsson, J; Pihl, M | 2 |
| Achenbach, P; Agardh, CD; Bonifacio, E; Furmaniak, J; Hansen, JM; Hausmann, S; Krause, S; Landherr, U; Lernmark, A; Link, K; Lynch, KF; Powell, M; Rees-Smith, B; Ziegler, AG | 1 |
| Chen, Z; Dang, H; Kaufman, DL; Nguyen, AV; Tian, J | 1 |
| Hinke, SA | 1 |
| Casas, R; Chéramy, M; Hampe, CS; Johansson, I; Ludvigsson, J; Skoglund, C | 1 |
| Akerman, L; Axelsson, S; Casas, R; Hjorth, M; Ludvigsson, J | 1 |
| Axelsson, S; Casas, R; Faresjö, M; Hjorth, M; Ludvigsson, J; Rydén, A | 1 |
| Larsson, HE; Lernmark, A | 1 |
| Casas, R; Chéramy, M; Hampe, CS; Ludvigsson, J; Skoglund, C | 1 |
| Casas, R; Chéramy, M; Hampe, CS; Ludvigsson, J | 1 |
5 review(s) available for aluminum sulfate and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of glutamic acid decarboxylase (GAD)-alum immunotherapy in recent-onset type 1 diabetes.
Topics: Alum Compounds; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Immunologic Factors; Immunotherapy | 2022 |
GAD65: a prospective vaccine for treating Type 1 diabetes?
Topics: Adaptive Immunity; Alum Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Vaccination | 2017 |
Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes.
Topics: Adjuvants, Immunologic; Adult; Alum Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Humans; Injections, Subcutaneous; Recombinant Proteins | 2008 |
GAD-alum (Diamyd)--a new concept for preservation of residual insulin secretion.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Alum Compounds; Animals; Child; Child, Preschool; Diabetes Mellitus, Type 1; Evidence-Based Medicine; Glutamate Decarboxylase; Humans; Immune Tolerance; Immunotherapy; Insulin; Insulin Secretion; Insulin-Secreting Cells; Middle Aged; Recombinant Proteins; Treatment Outcome; Young Adult | 2010 |
Does immune-tolerance treatment with Alum-formulated GAD65 protect insulin-production in the pancreatic islet β cells?
Topics: Adjuvants, Immunologic; Alum Compounds; Autoimmune Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Humans; Immune Tolerance; Immunization, Secondary; Injections, Subcutaneous; Vaccination | 2011 |
15 trial(s) available for aluminum sulfate and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial).
Topics: Alum Compounds; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Follow-Up Studies; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Immunoglobulin G | 2022 |
Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
Topics: Adolescent; Alum Compounds; Blood Glucose; Blood Glucose Self-Monitoring; C-Peptide; Child; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Glycemic Control; HLA-DR3 Antigen; Humans; Vitamin D; Young Adult | 2022 |
Latent Autoimmune Diabetes in Adults: Background, Safety and Feasibility of an Ongoing Pilot Study With Intra-Lymphatic Injections of GAD-Alum and Oral Vitamin D.
Topics: Adult; Aged; Alum Compounds; Diabetes Mellitus, Type 1; Feasibility Studies; Glucose Intolerance; Glutamate Decarboxylase; Humans; Insulin; Latent Autoimmune Diabetes in Adults; Middle Aged; Pilot Projects; Vitamin D | 2022 |
A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes.
Topics: Animals; Diabetes Mellitus, Type 1; gamma-Aminobutyric Acid; Glucagon; Glutamate Decarboxylase; Islets of Langerhans | 2022 |
Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Topics: C-Peptide; Cytokines; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Haplotypes; HLA Antigens; Humans; Immunity, Cellular; Interleukin-10; Interleukin-13; Interleukin-5 | 2023 |
Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD
Topics: Adolescent; Alum Compounds; Autoantibodies; C-Peptide; Child; Cytokines; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Finland; Glutamate Decarboxylase; Hemagglutinins; Humans; Immune System; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Insulin; Insulin Secretion; Male; Normal Distribution; Sweden; Time Factors; Vaccination; Young Adult | 2017 |
Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
Topics: Adolescent; Alum Compounds; Cell Proliferation; Child; Cytokines; Diabetes Mellitus, Type 1; Female; Glutamate Decarboxylase; Humans; Immunoglobulin G; Immunomodulation; Immunophenotyping; Leukocytes, Mononuclear; Lymph Nodes; Lymphocyte Activation; Male; Pilot Projects; Th2 Cells; Treatment Outcome; Young Adult | 2018 |
Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.
Topics: Adjuvants, Immunologic; Adolescent; Alum Compounds; Autoantigens; Child; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Glutamate Decarboxylase; Humans; Immunosuppression Therapy; Interleukin-2 Receptor alpha Subunit; Interleukin-7 Receptor alpha Subunit; Lymphocyte Activation; Male; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Time Factors; Treatment Outcome | 2013 |
Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
Topics: Adult; Alum Compounds; Autoantibodies; Diabetes Mellitus, Type 1; Female; Glutamate Decarboxylase; Humans; Immunity, Cellular; Immunity, Humoral; Immunoglobulin G; Insulin; Leukocytes, Mononuclear; Male; Middle Aged | 2013 |
GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
Topics: Adolescent; Alum Compounds; Autoantibodies; C-Peptide; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Injections, Subcutaneous; Insulin; Insulin Secretion; Male; Young Adult | 2014 |
GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.
Topics: Adult; Aged; Alum Compounds; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Disease Progression; Double-Blind Method; Female; Glucose Intolerance; Glutamate Decarboxylase; Humans; Insulin-Secreting Cells; Male; Middle Aged; Vaccination; Vaccines, Synthetic | 2014 |
GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
Topics: Adjuvants, Immunologic; Adolescent; Alum Compounds; Antibodies; Area Under Curve; Autoantibodies; Biocatalysis; C-Peptide; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Glutamate Decarboxylase; Humans; Immune Sera; Immunity, Humoral; Immunoglobulin E; Immunoglobulin G; Immunotherapy, Active; Tetanus Toxoid; Treatment Outcome | 2010 |
GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
Topics: Adolescent; Alum Compounds; Autoantibodies; CD4-Positive T-Lymphocytes; Cell Count; Child; Diabetes Mellitus, Type 1; Female; Forkhead Transcription Factors; Gene Expression; Glutamate Decarboxylase; Humans; Immunosuppression Therapy; Interferon-gamma; Interleukin-2 Receptor alpha Subunit; Interleukins; Leukocytes, Mononuclear; Lymphocyte Activation; Male; T-Lymphocytes, Regulatory; Th2 Cells; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.
Topics: Adolescent; Alum Compounds; Autoantibodies; Child; Diabetes Mellitus, Type 1; Epitopes; Glutamate Decarboxylase; Humans | 2012 |
Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.
Topics: Adolescent; Adult; Aged; Alum Compounds; Autoantibodies; Diabetes Mellitus, Type 1; Female; Glutamate Decarboxylase; Humans; Immunoglobulin G; Male; Middle Aged; Phenotype; Stiff-Person Syndrome | 2013 |
8 other study(ies) available for aluminum sulfate and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.
Topics: Alum Compounds; CD8-Positive T-Lymphocytes; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Humans; Immunity; Leukocytes, Mononuclear | 2022 |
Antigen-based Immunotherapy Improves Glycemic Metrics and β-Cell Function.
Topics: Alum Compounds; Benchmarking; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Glycemic Control; HLA-DR3 Antigen; Humans; Immunotherapy | 2022 |
Preventing type 1 diabetes in late-stage pre-diabetic NOD mice with insulin: A central role for alum as adjuvant.
Topics: Animals; C-Peptide; CD8-Positive T-Lymphocytes; Diabetes Mellitus, Type 1; Female; Forkhead Transcription Factors; Humans; Infant, Newborn; Insulin; Mice; Mice, Inbred NOD; Mice, Obese; Peptides; Prediabetic State | 2022 |
A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes.
Topics: Adult; Autoantibodies; Diabetes Mellitus, Type 1; Glucose Intolerance; Glutamate Decarboxylase; Humans; Injections, Intralymphatic; Latent Autoimmune Diabetes in Adults; Leukocytes, Mononuclear; Middle Aged; Pilot Projects | 2023 |
Combined Etanercept, GAD-alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes.
Topics: Adolescent; Aged; Alum Compounds; Child; Diabetes Mellitus, Type 1; Etanercept; Female; Glutamate Decarboxylase; Humans; Insulin; Leukocytes, Mononuclear; Male; Pilot Projects; Vitamin D | 2021 |
Antigen-specific immunotherapy and influenza vaccination in type 1 diabetes: timing is everything.
Topics: Alum Compounds; Animals; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Humans; Immunotherapy; Influenza Vaccines; Vaccination; Vaccines, Conjugate | 2017 |
Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting β-cell replication in newly diabetic NOD mice.
Topics: Alum Compounds; Animals; Autoimmunity; Blood Glucose; Cell Division; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Interleukin-10; Interleukin-4; Mice; Mice, Inbred NOD; Proinsulin; T-Lymphocytes, Regulatory | 2014 |
Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
Topics: Adolescent; Alum Compounds; Autoantibodies; Child; Diabetes Mellitus, Type 1; Follow-Up Studies; Forkhead Transcription Factors; Glutamate Decarboxylase; Humans; Immunologic Factors; Insulin; Interferon-gamma; Interleukins; Monocytes; Multicenter Studies as Topic; Protein Tyrosine Phosphatases; Randomized Controlled Trials as Topic; Th2 Cells; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2010 |